Metabasis inks multimillion-dollar development deal

Metabasis Therapeutics will pocket $5 million on the completion of a new collaboration deal with Merck to develop small molecule therapies that can treat a variety of conditions -- including type 2 diabetes, hyperlipidemia and obesity -- by activation of an enzyme in the liver called AMP-activated Protein Kinase. Milestones for a successful commercial drug launch would push Metabasis' take to $54 million, with additional indications adding another $20 million in new milestones.

"We have been very impressed with the expertise and professionalism that we have experienced during the joint hepatitis C project we began with Merck in 2004," said Dr. Paul Laikind, chairman, president and CEO of Metabasis. "Combining efforts with Merck scientists on the AMPK project will give us the greatest chance of developing a new drug to treat a devastating group of diseases."

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.